Randomized Clinical Trial
Copyright ©The Author(s) 2023.
World J Clin Cases. Nov 16, 2023; 11(32): 7814-7821
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7814
Table 3 Secondary outcomes
Outcome
Aspirin group (n = 30)
No aspirin group (n = 30)
P value
mRS score at 90 d, median (IQR)2 (1-3)3 (2-4)0.04
Bleeding complications, n (%)2 (6.7)2 (6.7)1.00
Intracranial hemorrhage, n (%)0 (0)0 (0)-
Gastrointestinal bleeding, n (%)0 (0)0 (0)-
Other major bleeding, n (%)2 (6.7)2 (6.7)-
Mortality rate, n (%)3 (10)4 (13.3)0.69